Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor

J Antimicrob Chemother. 2012 Nov;67(11):2779-81. doi: 10.1093/jac/dks260. Epub 2012 Jul 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / pharmacokinetics*
  • Antiretroviral Therapy, Highly Active / methods*
  • Cyclohexanes / administration & dosage
  • Cyclohexanes / pharmacokinetics*
  • Drug Interactions*
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Maraviroc
  • Middle Aged
  • Multicenter Studies as Topic
  • Nitriles
  • Plasma / chemistry
  • Pyridazines / administration & dosage
  • Pyridazines / pharmacokinetics*
  • Pyrimidines
  • Ritonavir / administration & dosage
  • Triazoles / administration & dosage
  • Triazoles / pharmacokinetics*

Substances

  • Anti-HIV Agents
  • Cyclohexanes
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Triazoles
  • etravirine
  • Maraviroc
  • Ritonavir